Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies

mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody responses for the control of continuously emerging S...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 13; p. 864718
Main Authors: Vogt, Anne-Cathrine S., Jörg, Lukas, Martina, Byron, Krenger, Pascal S., Chang, Xinyue, Zeltins, Andris, Vogel, Monique, Mohsen, Mona O., Bachmann, Martin F.
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 16.06.2022
Subjects:
2019-nCoV Vaccine mRNA-1273
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunoglobulin G
Immunology
mRNA
RNA, Messenger - genetics
SARS-CoV-2
SARS-CoV-2 - genetics
vaccine
virus-like particles
COVID-19
virus-like particles
SARS-CoV-2
vaccine
mRNA
ISSN:1664-3224, 1664-3224
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody responses for the control of continuously emerging SARS-CoV-2 variants of concern (VoCs) and to overcome other obstacles such as supply shortage, costs and reduced safety issues or inadequatly induced immune-responses. In this study, we investigated the antibody responses induced by heterologous prime-boost with vaccines based on mRNA and virus-like particles (VLPs). The VLP-based mCuMV TT -RBM vaccine candidate and the approved mRNA-1273 vaccine were used for this purpose. We find that homologous prime boost regimens with either mRNA or VLP induced high levels of high avidity antibodies. Optimal antibody responses were, however, induced by heterologous regimens both for priming with mRNA and boosting with VLP and vice versa, priming with VLP and boosting with mRNA. Thus, heterologous prime boost strategies may be able to optimize efficacy and economics of novel vaccine strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Allan Randrup Thomsen, University of Copenhagen, Denmark
These authors have contributed equally to this work
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Reviewed by: Stephanie Longet, University of Oxford, United Kingdom; Kishu Ranjan, Yale University, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.864718